KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Debt (2020 - 2025)

Historic Total Debt for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $20.8 million.

  • Recursion Pharmaceuticals' Total Debt fell 2752.62% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 2752.62%. This contributed to the annual value of $27.4 million for FY2024, which is 230341.51% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Total Debt of $20.8 million as of Q3 2025, which was down 2752.62% from $22.9 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Total Debt peaked at $31.0 million during Q2 2024, and registered a low of $536000.0 during Q4 2022.
  • For the 5-year period, Recursion Pharmaceuticals' Total Debt averaged around $9.7 million, with its median value being $1.2 million (2023).
  • In the last 5 years, Recursion Pharmaceuticals' Total Debt plummeted by 9445.42% in 2021 and then surged by 258658.01% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Total Debt (Quarter) stood at $633000.0 in 2021, then fell by 15.32% to $536000.0 in 2022, then skyrocketed by 113.06% to $1.1 million in 2023, then soared by 2303.42% to $27.4 million in 2024, then fell by 24.14% to $20.8 million in 2025.
  • Its Total Debt stands at $20.8 million for Q3 2025, versus $22.9 million for Q2 2025 and $25.0 million for Q1 2025.